EcoDrugPlus

Histone Deacetylase 7b

Ensembl ID : ENSDARG00000073850
Gene Symbol: HDAC7B
5 Cross references
197 Possible Orthologues:

Histone Deacetylase 8

Ensembl ID : ENSDARG00000003021
Gene Symbol: HDAC8
5 Cross references
206 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide-Gated Potassium Channel 4

Ensembl ID : ENSDARG00000061685
Gene Symbol: HCN4
3 Enzyme and pathways 5 Cross references
218 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide-Gated Potassium Channel 4l

Ensembl ID : ENSDARG00000074419
Gene Symbol: HCN4L
5 Cross references
211 Possible Orthologues:

Hypocretin (Orexin) Receptor 2

Ensembl ID : ENSDARG00000023722
Gene Symbol: HCRTR2
8 Enzyme and pathways 5 Cross references
201 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSDARG00000079123
Gene Symbol: IKBKB
54 Enzyme and pathways 5 Cross references
198 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSDARG00000074283
Gene Symbol: INPP5D
19 Enzyme and pathways 5 Cross references
216 Possible Orthologues:

Insulin Receptor A

Ensembl ID : ENSDARG00000011948
Gene Symbol: INSRA
11 Enzyme and pathways 5 Cross references
231 Possible Orthologues:

Insulin Receptor B

Ensembl ID : ENSDARG00000071524
Gene Symbol: INSRB
5 Cross references
201 Possible Orthologues:

Insulin-Like Growth Factor 1a Receptor

Ensembl ID : ENSDARG00000027423
Gene Symbol: IGF1RA
9 Enzyme and pathways 5 Cross references
206 Possible Orthologues:

Insulin-Like Growth Factor 1b Receptor

Ensembl ID : ENSDARG00000034434
Gene Symbol: IGF1RB
5 Cross references
204 Possible Orthologues:

Integrin Alpha 4

Ensembl ID : ENSDARG00000103056
Gene Symbol: ITGA4
7 Enzyme and pathways 5 Cross references
226 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).